# Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

> **NCT00867100** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 700 mg IV
- **DRUG:** 350 mg SC
- **DRUG:** Placebo
- **DRUG:** 140 mg SC

## Key facts

- **NCT ID:** NCT00867100
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867100, "Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00867100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*